Overview

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.

Phase:

Phase 3

Details

Lead Sponsor:

Mylan Inc.

Collaborator:

Mylan GmbH

Treatments:

Insulin
Insulin Glargine
Insulin Lispro
Insulin, Globin Zinc